Market: NASD |
Currency: USD
Address: 645 Summer Street
Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
📈 Ikena Oncology, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$23.00
-
Upside/Downside from Analyst Target:
1,508.39%
-
Broker Call:
2
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
50-100%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Ikena Oncology, Inc.
| Date | Reported EPS |
|---|
| 2025-08-07 | - |
| 2025-07-24 | -0.61 |
| 2025-05-08 | -1.79 |
| 2025-03-06 | -2.28 |
| 2024-11-07 | -2.34 |
| 2024-08-08 | -3.24 |
| 2024-05-13 | -3.37 |
| 2024-03-12 | -4.8 |
| 2023-11-09 | -4.8 |
| 2023-08-10 | -5.28 |
| 2023-05-15 | -4.68 |
| 2023-03-14 | -4.68 |
| 2022-11-07 | -5.76 |
| 2022-08-11 | -6.84 |
| 2022-05-12 | -5.64 |
| 2022-03-17 | 2.88 |
| 2021-11-10 | -4.8 |
| 2021-08-12 | -4.2 |
| 2021-05-13 | -30.24 |
📰 Related News & Research
No related articles found for "ikena oncology".
